Overview of the side-effects of FDA-and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Constantinescu C, Pasca S, Zimta AA, Tat T, Rus I, Teodorescu P, Iluta S, Tanase A, Colita A, Sigurjonsson O, Einsele H, Tomuleasa C (2020)
Publication Type: Journal article
Publication year: 2020
Journal
Book Volume: 9
Pages Range: 1-15
Article Number: 2903
Journal Issue: 9
DOI: 10.3390/jcm9092903
Abstract
In the last decade there has been tremendous effort in offering better therapeutic management strategies to patients with hematologic malignancies. These efforts have ranged from biological to clinical approaches and resulted in the rapid development of new approaches. The main “problem” that comes with the high influx of newly approved drugs, which not only influences hematologists that frequently work with these drugs but also affects other healthcare professionals that work with hematologists in patient management, including intensive care unit (ICU) physicians, is they have to keep up within their specialty and, in addition, with the side-effects that can occur when encountering hematology-specific therapies. Nonetheless, there are few people that have an in-depth understanding of a specialty outside theirs. Thus, this manuscript offers an overview of the most common side-effects caused by therapies used in hematology nowadays, or that are currently being investigated in clinical trials, with the purpose to serve as an aid to other specialties. Nevertheless, because of the high amount of information on this subject, each chapter will offer an overview of the side-effects of a drug class with each reference of the section being intended as further reading.
Involved external institutions
Institute of Oncology Prof. Dr. Ion Chiricuta
Romania (RO)
Landspítali / National University Hospital of Iceland
Iceland (IS)
Universitätsklinikum Würzburg
Germany (DE)
Iuliu Hațieganu University of Medicine and Pharmacy / Universitatea de Medicină și Farmacie "Iuliu Hațieganu" (UMF Cluj)
Romania (RO)
Spitalul Clinic Fundeni Bucuresti
Romania (RO)
Romania (RO)
Landspítali / National University Hospital of Iceland
Iceland (IS)
Universitätsklinikum Würzburg
Germany (DE)
Iuliu Hațieganu University of Medicine and Pharmacy / Universitatea de Medicină și Farmacie "Iuliu Hațieganu" (UMF Cluj)
Romania (RO)
Spitalul Clinic Fundeni Bucuresti
Romania (RO)
How to cite
APA:
Constantinescu, C., Pasca, S., Zimta, A.-A., Tat, T., Rus, I., Teodorescu, P.,... Tomuleasa, C. (2020). Overview of the side-effects of FDA-and/or EMA-approved targeted therapies for the treatment of hematological malignancies. Journal of Clinical Medicine, 9(9), 1-15. https://doi.org/10.3390/jcm9092903
MLA:
Constantinescu, Catalin, et al. "Overview of the side-effects of FDA-and/or EMA-approved targeted therapies for the treatment of hematological malignancies." Journal of Clinical Medicine 9.9 (2020): 1-15.
BibTeX: Download